Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Entecavir

FDA-approved product (tablet, oral), marketed as Baraclude, Entecavir.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Entecavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis B virus infection
  • Liver disease
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA pharmacologic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF10; FDA class Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Entecavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Entecavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

    NCT04147208 · start 2019-02-28

    Registered record
    Registry ID
    NCT04147208
    Conditions
    Chronic HBV Infection
    Interventions
    GLS4; RTV; ETV
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-02-28
    Completion
    2023-09-14
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic HBV Infection
    InterventionGLS4; RTV; ETV
    PhasePhase 2
    Registry statusCompleted

  • Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b

    NCT04195074 · start 2019-01-01

    Registered record
    Registry ID
    NCT04195074
    Conditions
    Chronic Hepatitis b
    Interventions
    Entecavir; Tenofovir Disoproxil Fumarate; Tenofovir Alafenamide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-01-01
    Completion
    2024-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis b
    InterventionEntecavir; Tenofovir Disoproxil Fumarate; Tenofovir Alafenamide
    PhaseNot applicable
    Registry statusUnknown

  • Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers

    NCT03847246 · start 2018-12-04

    Registered record
    Registry ID
    NCT03847246
    Conditions
    Chronic Hepatitis b
    Interventions
    Baraclude® tablets,1.0 mg; Entecavir tablets,1.0 mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-12-04
    Completion
    2018-12-28
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis b
    InterventionBaraclude® tablets,1.0 mg; Entecavir tablets,1.0 mg
    PhaseNot applicable
    Registry statusCompleted

  • Carvedilol for Prevention of Esophageal Varices Progression

    NCT03736265 · start 2017-10-09

    Registered record
    Registry ID
    NCT03736265
    Conditions
    Cirrhosis, Liver; Portal Hypertension
    Interventions
    Carvedilol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-10-09
    Completion
    2022-12-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis, Liver; Portal Hypertension
    InterventionCarvedilol
    PhaseNot applicable
    Registry statusUnknown

  • A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B

    NCT03258710 · start 2017-10-02

    Registered record
    Registry ID
    NCT03258710
    Conditions
    Hepatitis B, Chronic
    Interventions
    Tenofovir Disoproxil Fumarate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-10-02
    Completion
    2019-11-25
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionTenofovir Disoproxil Fumarate
    PhasePhase 4
    Registry statusCompleted

  • RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection

    NCT04032860 · start 2017-07-01

    Registered record
    Registry ID
    NCT04032860
    Conditions
    HCC; HBV Coinfection
    Interventions
    Tenofovir Disoproxil; Entecavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-07-01
    Completion
    2026-07-01
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCC; HBV Coinfection
    InterventionTenofovir Disoproxil; Entecavir
    PhasePhase 4
    Registry statusUnknown

  • Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

    NCT02738008 · start 2016-03

    Registered record
    Registry ID
    NCT02738008
    Conditions
    Hepatitis B
    Interventions
    ARC-520 Injection; entecavir; tenofovir; antihistamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-03
    Completion
    2016-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    InterventionARC-520 Injection; entecavir; tenofovir; antihistamine
    PhasePhase 2
    Registry statusTerminated

  • Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir

    NCT03236610 · start 2016-01-01

    Registered record
    Registry ID
    NCT03236610
    Conditions
    Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48
    Interventions
    tenofovir monotherapy; tenofovir plus entecavir combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-01-01
    Completion
    2019-06-30
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48
    Interventiontenofovir monotherapy; tenofovir plus entecavir combination
    PhasePhase 3
    Registry statusUnknown

  • Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)

    NCT02577029 · start 2015-12

    Registered record
    Registry ID
    NCT02577029
    Conditions
    Hepatitis B; Hepatitis D
    Interventions
    ARC-520; entecavir; pegylated interferon alpha 2a; tenofovir disoproxil; antihistamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-12
    Completion
    2016-12
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B; Hepatitis D
    InterventionARC-520; entecavir; pegylated interferon alpha 2a; tenofovir disoproxil +1 more
    PhasePhase 2
    Registry statusTerminated

  • Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides

    NCT02644538 · start 2015-12

    Registered record
    Registry ID
    NCT02644538
    Conditions
    Hepatitis B
    Interventions
    PegIFN alfa-2a
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-12
    Completion
    2018-12
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    InterventionPegIFN alfa-2a
    PhasePhase 4
    Registry statusUnknown

  • A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

    NCT02604199 · start 2015-09

    Registered record
    Registry ID
    NCT02604199
    Conditions
    Hepatitis B
    Interventions
    ARC-520 Injection; placebo; entecavir; tenofovir; antihistamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-09
    Completion
    2017-01
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    InterventionARC-520 Injection; placebo; entecavir; tenofovir +1 more
    PhasePhase 2
    Registry statusTerminated

  • Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

    NCT02496897 · start 2015-07

    Registered record
    Registry ID
    NCT02496897
    Conditions
    Hepatitis B
    Interventions
    FP-02.2 Vaccine; Placebo; IC31® Adjuvant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-07
    Completion
    2018-06-05
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    InterventionFP-02.2 Vaccine; Placebo; IC31® Adjuvant
    PhasePhase 1
    Registry statusCompleted

  • Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers

    NCT02777814 · start 2015-05-01

    Registered record
    Registry ID
    NCT02777814
    Conditions
    Colorectal Neoplasms
    Interventions
    Entecavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-05-01
    Completion
    2019-11
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Neoplasms
    InterventionEntecavir
    PhasePhase 2
    Registry statusUnknown

  • An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients

    NCT02560649 · start 2015-05

    Registered record
    Registry ID
    NCT02560649
    Conditions
    Chronic Hepatitis B
    Interventions
    Peginterferon alfa-2a plus Entecavir; Peginterferon alfa-2a plus Lamivudine; Peginterferon alfa-2a plus Adefovir; Peginterferon alfa-2a plus Tenofovir; Entecavir; Lamivudine; Adefovir; Tenofovir disoproxil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-05
    Completion
    2017-02
    Enrolment
    324

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionPeginterferon alfa-2a plus Entecavir; Peginterferon alfa-2a plus Lamivudine; Peginterferon alfa-2a plus Adefovir; Peginterferon alfa-2a plus Tenofovir +4 more
    PhasePhase 4
    Registry statusUnknown

  • A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)

    NCT02327416 · start 2014-10

    Registered record
    Registry ID
    NCT02327416
    Conditions
    Hepatitis B, Chronic
    Interventions
    Y peginterferon alfa-2b; Granulocyte-macrophage colony stimulating factor; Entecavir and or adefovir dipivoxil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-10
    Completion
    2019-06
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionY peginterferon alfa-2b; Granulocyte-macrophage colony stimulating factor; Entecavir and or adefovir dipivoxil
    PhasePhase 3
    Registry statusUnknown